PHGE
USDBiomX Inc. COmmon Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$0.460
Kõrge
$0.463
Madal
$0.435
Maht
0.13M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
11.5M
Tööstusharu
Biotehnoloogia
Riik
Israel
Kauplemisstatistika
Keskmine maht
0.13M
Börs
ASE
Valuuta
USD
52 nädala vahemik
Seotud uudised
BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference
NESS ZIONA, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic
HC Wainwright & Co. Maintains Buy on BiomX, Lowers Price Target to $15
HC Wainwright & Co. analyst Joseph Pantginis maintains BiomX with a Buy and lowers the price target from $21 to $15.
BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates
In March 2025, BiomX announced positive topline results of the phase 2 trial evaluating BX211 for the treatment of diabetic foot osteomyelitis (DFO) BX004 Phase 2b study in Cystic Fibrosis (CF) on track to report
BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025
NESS ZIONA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic
Seotud aktsiad
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.